# Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)

> **NCT03065023** · PHASE1,PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** MK-4621

## Key facts

- **NCT ID:** NCT03065023
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-25
- **Primary completion:** 2018-05-18
- **Final completion:** 2018-05-18
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Group B not started for business reasons.
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03065023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03065023, "Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03065023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*